Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy

Theranostics

Volumn 2, Issue 1, 2012, Pages 3-44

  Yu, Mi Kyung ^a   Park, Jinho ^a   Jon, Sangyong ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

Bioconjugation; Long circulation; Magnetic nanoparticles; Multifunctional nanoparticles; Surface engineering; Targeting ligand

Indexed keywords

APTAMER; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; BIND 014; CALAA 01; CETUXIMAB; CHITOSAN; CILENGITIDE; CONTRAST MEDIUM; CYCLODEXTRIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; FLUORESCENT DYE; IMMUNOLIPOSOME; LIPOSOME; MACROGOL; MBP 426; MCC 465; NANOMATERIAL; NANOPARTICLE; OXALIPLATIN; PACLITAXEL; PEGDINETANIB; POLYETHYLENEIMINE; POLYGLACTIN; PROTEIN P53; RITUXIMAB; SGT53 01; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ADVANCED CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER MODEL; CANCER THERAPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONJUGATION; DRUG DELIVERY SYSTEM; ENGINEERING; ESOPHAGEAL ADENOCARCINOMA; HUMAN; IMAGING SYSTEM; IN VIVO STUDY; KAPOSI SARCOMA; LIPOSOMAL DELIVERY; LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PANCREAS CANCER; REVIEW; SOLID TUMOR; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURFACE PROPERTY;

EID: 84863666971     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.3463     Document Type: Review

References (227)

1. Boyle P, Levin B. World Cancer Report. World Health Organization Press; 2008.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010; 60: 277-300.
3. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumorselective macromolecular drug targeting. Adv Enzyme Regul. 2001; 41: 189-207.
4. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002; 2: 705-63.
5. Torchilin VP. Nanoparticulates as drug carriers. Imperial college press; 2006.
6. Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, Brown PA, et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater. 2011; 10: 389-97.
7. Cho EC, Glaus C, Chen J, Welch MJ, Xia Y. Inorganic nanoparticle-based contrast agents for molecular imaging. Trends Mol Med. 2010; 16: 561-73.
8. Lee S, Kwon IC, Kim K. Multifunctional Nanoparticles for Cancer Theragnosis. In: Chen X, ed. Nanoplatform-Based Molecular Imaging. Hoboken, NJ, USA: John Wiley & Sons, Inc. 2011.
9. Kievit FM, Zhang M. Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc Chem Res. 2011; [Epub ahead of print].
10. Varadan VK, Chen L, Xie J. Biomedical applications of magnetic nanoparticles, in Nanomedicine: design and applications of magnetic nanomaterials, nanosensors and nanosystems. Chichester, UK: John Wiley & Sons, Inc. 2008.
11. Jones A, Harris AL. New developments in angiogenesis: a major mechanism for tumor growth and target for therapy. Cancer J Sci Am. 1998; 4: 209-17.
12. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998; 95: 4607-12.
13. Shubik P. Vascularization of tumors: a review. J Cancer Res Clin Oncol. 1982; 103: 211-26.
14. Yaun F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995; 55: 3752-56.
15. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004; 303: 1818-22.
16. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008; 60:1615-26.
17. Gabizon A, Martin F. Polyethylene glycolcoated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs. 1997; 54: 15-21.
18. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003; 42: 419-36.
19. Allen TM, Martin FJ. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol. 2004; 31: 5-15.
20. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophorfree, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006; 12: 1317-24.
21. Miele E, Spinelli GP, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomed. 2009; 4: 99-105.
22. Bae YH. Drug targeting and tumor heterogeneity. J Control Release. 2009; 133: 2-3.
23. Mishra S, Webster P, Davis ME. PEGylation significantly affects cellular uptake and intracellular trafficking of nonviral gene delivery particles. Eur J Cell Biol. 2004; 83: 97-111.
24. Romberg B, Hennink W, Storm G. Sheddable Coatings for Long-Circulating Nanoparticles. Pharm Res. 2008; 25: 55-71.
25. Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial. Clin Cancer Res. 1999; 5: 3645-52.
26. Gullotti E, Yeo Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm. 2009; 6:1041-51.
27. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nature Rev Cancer. 2002; 2: 48-58.
28. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007; 2: 751-60.
29. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006; 6: 559-65.
30. Shi J, Xiao Z, Kamaly N, Farokhzad OC. Self-Assembled Targeted Nanoparticles: Evolution of Technologies and Bench to Bedside Translation. Acc Chem Res. 2011; [Epub ahead of print]
31. Krown SE, Northfelt DW, Osoba D, Stewart JS. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin Oncol. 2004; 31: 36-52.
32. Mrózek E, Rhoades CA, Allen J, Hade EM, Shapiro CL. Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients. Ann Oncol. 2005; 16: 1087-93.
33. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for firstline treatment of metastatic breast cancer. Ann Oncol. 2004; 15: 440-9.
34. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol. 2000; 11: 69-72.
35. Petrelli F, Borgonovo K, Barni S. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Expert Opin Pharmacother. 2010; 11: 1413-32.
36. Lim WT, Tan EH, Toh CK, Hee SW, Leong SS, Ang PC, et al. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann Oncol. 2010; 21: 382-8.
37. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: fromconcept to clinic. Mol Pharmaceutics. 2009; 6: 659-68.
38. Sankhala KK, Mita AC, Adinin R, Wood L, Beeram M, Bullock S, et al. A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin. J Clin Oncol. 2009; 27: S2535.
39. Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol. 2004; 15: 517-25.
40. [Internet] BIND Biosciences initiates Phase 1 clinical study of BIND-014. http://www.bindbio.com/content/pages/news/news_detail.jsp/q/newsid/55 (1/18/2011).
41. Nemunaitis J, Senzer N, Bedell C, Nunan R, Sleer L, Chang E. A phase I study of escalating doses of SGT-53 for intravenous infusion of patients with advanced solid tumors. Mol Ther. 2009; 17: S226.
42. Kumar CS. Nanomaterials for medical diagnosis and therapy. Wiley-VCH. 2007.
43. Montet X, Funovics M, Montet-Abou K, Weissleder R, Josephson L. Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem. 2006; 49: 6087-93.
44. Gao J, Gu H, Xu B. Multifunctional magnetic nanoparticles: design, synthesis, and biomedical applications. Acc Chem Res. 2009; 42: 1097-107.
45. Das M, Mishra D, Dhak P, Gupta S, Maiti TK, Basak A, et al. Biofunctionalized, Phosphonate-Grafted, Ultrasmall Iron Oxide Nanoparticles for Combined Targeted Cancer Therapy and Multimodal Imaging. Small. 2009; 5: 2883-93.
46. Pan D, Caruthers SD, Hu G, Senpan A, Scott MJ, Gaffney PJ, et al. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J Am Chem Soc. 2008; 130: 9186-7.
47. Bae KH, Lee K, Kim C, Park TG. Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. Biomaterials. 2011; 32: 176-84.
48. James JS, Dubs G. FDA approves new kind of lymphoma treatment. AIDS Treat News 1997; 284: 2-3.
49. Albanell J, Baselga J. Trastuzumab. A humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs Today. 1999; 35: 931-46.
50. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005; 69: 11-6.
51. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408-17.
52. Hadjipanayis CG, Machaidze R, Kaluzova M, Wang L, Schuette AJ, Chen H, et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 2010; 70: 6303-12.
53. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004; 22: 969-76.
54. Raghavan R, Brady ML, Rodríguez-Ponce MI, Hartlep A, Pedain C, Sampson JH. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus. 2006; 20: E12.
55. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994; 91: 2076-80.
56. Hadjipanayis CG, Fellows-Mayle W, Deluca NA. Therapeutic efficacy of a herpes simplex virus in combination with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery. Mol Ther. 2008; 16: 1783-8.
57. Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL. High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol. 1994; 266: R292-305.
58. Ling Y, Wei K, Luo Y, Gao X, Zhong S. Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. Biomaterials. 2011; 32: 7139-50.
59. Wente MN, Jain A, Kono E, Berberat PO, Giese T, Reber HA, et al. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas 2005; 31: 119-25.
60. Chen G, Chen W, Wu Z, Yuan R, Li H, Gao J, et al. MRI-visible polymeric vector bearing CD3 single chain antibody for gene delivery to T cells for immunosuppression. Biomaterials. 2009; 30: 1962-70.
61. Tromsdorf UI, Bigall NC, Kaul MG, Bruns OT, Nikolic MS, Mollwitz B, et al. Size and surface effects on the MRI relaxivity of manganese ferrite nanoparticle contrast agents. Nano Lett 2007; 7: 2422-7.
62. Olenchock BA, Guo R, Carpenter JH, Jordan M, Topham MK, Koretzky GA, et al. Disruption of diacylglycerol metabolism impairs the induction of T cell anergy. Nat Immunol 2006; 7: 1174-81.
63. Zhong XP, Hainey EA, Olenchock BA, Zhao H, Topham MK, Koretzky GA. Regulation of T cell receptor-induced activation of the Ras-ERK pathway by diacylglycerol kinase zeta. J Biol Chem. 2002; 277: 31089-98.
64. Lu RM, Chang YL, Chen MS, Wu HC. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials. 2011; 32: 3265-74.
65. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4: 915-25.
66. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009; 27: 1667-74.
67. Ding S, Merkulova-Rainon T, Han ZC, Tobelem G. HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood. 2003; 101: 4816-22.
68. Wang AZ, Gu F, Zhang L, Chan JM, Radovic-Moreno A, Shaikh MR, et al. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther. 2008; 8: 1063-70.
69. McCarthy JR, Bhaumik J, Karver MR, Sibel Erdem S, Weissleder R. Targeted nanoagents for the detection of cancers. Mol Oncol. 2010; 4: 511-28.
70. Beekman KW, Colevas AD, Cooney K, Dipaola R, Dunn RL, Gross M, et al. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer. 2006; 4: 299-302.
71. Kumar M, Yigit M, Dai G, Moore A, Medarova Z. Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res. 2010; 70: 7553-61.
72. Perey L, Hayes DF, Maimonis P, Abe M, O'Hara C, Kufe DW. Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinomaassociated antigen. Cancer Res. 1992; 52: 2563-8.
73. Veiseh O, Sun C, Fang C, Bhattarai N, Gunn J, Kievit F, et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res. 2009; 69: 6200-7.
74. Lyons SA, O'Neal J, Sontheimer H. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia. 2002; 39: 162-73.
75. Packer RJ, Cogen P, Vezina G, Rorke LB. Medulloblastoma: clinical and biologic aspects. Neuro Oncol. 1999; 1: 232-50.
76. Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton BA, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 2004; 64: 7794-800.
77. Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, et al. Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res. 2007; 67: 6882-8.
78. Mok H, Park JW, Park TG. Enhanced intracellular delivery of quantum dot and adenovirus nanoparticles triggered by acidic pH via surface charge reversal. Bioconjugate Chem. 2008; 19: 797-801.
79. Min KH, Kim JH, Bae SM, Shin H, Kim MS, Park S, et al. Tumoral acidic pH-responsive MPEG-poly(betaaminoester) polymeric micelles for cancer targeting therapy. J Control Release. 2010; 144: 259-66.
80. Sethuraman VA, Na K, Bae YH. pH-responsive sulfonamide/PEI system for tumor specific gene delivery: an in vitro study. Biomacromolecules. 2006; 7: 64-70.
81. Mok H, Veiseh O, Fang C, Kievit FM, Wang FY, Park JO, et al. pH-Sensitive siRNA nanovector for targeted gene silencing and cytotoxic effect in cancer cells. Mol Pharm. 2010; 7: 1930-9.
82. Lee Y, Fukushima S, Bae Y, Hiki S, Ishii T, Kataoka K. A protein nanocarrier from charge-conversion polymer in response to endosomal pH. J Am Chem Soc. 2007; 129: 5362-3.
83. Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, Dirix LY, et al. Vascular integrin αvβ3: A new prognostic indicator in breast cancer. Clin Cancer Res. 1998; 4: 2625-34.
84. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A. 2008; 105: 9343-8.
85. He X, Na MH, Kim JS, Lee GY, Park JY, Hoffman AS, et al. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor. Mol Pharm. 2011; 8: 430-8.
86. Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, Brown PA, et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater. 2011; 10: 389-97.
87. Simberg D, Duza T, Park JH, Essler M, Pilch J, Zhang L, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A. 2007; 104: 932-6.
88. Dvorak HF, Senger DR, Dvorak AM, Harvey VS, McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science. 1985; 227: 1059-61.
89. Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA. 1999; 96: 8663-8.
90. Pilch J, Brown DM, Komatsu M, Jarvinen TA, Yang M, Peters D, et al. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci USA. 2006; 103: 2800-4.
91. von Maltzahn G, Park JH, Lin KY, Singh N, Schwöppe C, Mesters R, et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater. 2011; 10: 545-52.
92. Park JH, von Maltzahn G, Zhang L, Schwartz MP, Ruoslahti E, Bhatia SN, et al. Magnetic Iron Oxide Nanoworms for Tumor Targeting and Imaging. Adv Mater. 2008; 20: 1630-5.
93. Zhang H, Ma Y, Sun XL. Recent developments in carbohydrate-decorated targeted drug/gene delivery. Med Res Rev. 2010; 30: 270-89.
94. Shen Z, Wei W, Tanaka H, Kohama K, Ma G, Dobashi T, et al. A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy. Pharmacol Res. 2011; 64: 410-9.
95. Kim EM, Jeong HJ, Moon MH. Asialoglycoprotein receptor targeted gene delivery using galactosylated Polyethylenimine- graft -Poly (ethylene glycol): In vitro and in vivo studies. J Control Release. 2005; 108: 557-67.
96. Yang Y, Zhang Z, Chen L, Gu W, Li Y. Galactosylated poly(2-(2-aminoethyoxy)ethoxy)phosphazene/DNA complex nanoparticles: in vitro and in vivo evaluation for gene delivery. Biomacromolecules. 2010; 11: 927-33.
97. Cho CS, Park IK, Cho CS. Galactosylated Poly (ethylene glycol)-Chitosan - graft- Polyethylenimine as a gene carrier for hepatocyte-targeting. J. Control Release. 2008; 131: 150-7.
98. Lu W, Zhang G, Zhang R, Flores LG 2nd, Huang Q, Gelovani JG, et al. Tumor sitespecific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res. 2010; 70: 3177-88.
99. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002; 2: 301-10.
100. Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE, et al. Nanoshell-mediated nearinfrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A. 2003; 100: 13549-54.
101. Hu M, Chen J, Li ZY, Au L, Hartland GV, Li X, et al. Gold nanocages: engineering their structure for biomedical applications. Adv Mater. 2005; 17: 2255-61.
102. Melancon MP, Lu W, Yang Z, Zhang R, Cheng Z, Elliot AM, et al. In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy. Mol Cancer Ther. 2008; 7: 1730-9.
103. Lu W, Xiong C, Zhang G, Huang Q, Zhang R, Zhang JZ, et al. Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analogconjugated hollow gold nanospheres. Clin Cancer Res. 2009; 15: 876-86.
104. Foraker AB, Khantwal CM, Swaan PW. Current perspectives on the cellular uptake and trafficking of riboflavin. Adv Drug Deliv Rev. 2003; 55: 1467-83.
105. Karande AA, Sridhar L, Gopinath KS, Adiga PR. Riboflavin carrier protein: a serum and tissue marker for breast carcinoma. Int J Cancer. 2001; 95: 277-81.
106. Jayapaul J, Hodenius M, Arns S, Lederle W, Lammers T, Comba P, et al. FMN-coated fluorescent iron oxide nanoparticles for RCP-mediated targeting and labeling of metabolically active cancer and endothelial cells. Biomaterials. 2011; 32: 5863-71.
107. Lee CM, Jeong HJ, Kim EM, Kim DW, Lim ST, Kim HT, et al. Superparamagnetic iron oxide nanoparticles as a dual imaging probe for targeting hepatocytes in vivo. Magn Reson Med. 2009; 62: 1440-6.
108. Wilson DS, Szostak JW. In vitro selection of functional nucleic acids. Ann Rev Biochem. 1999; 68: 611-47.
109. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990; 249: 505-10.
110. Lee JF, Hesselberth JR, Meyers LA, Ellington AD. Aptamer database. Nucleic Acids Res. 2004; 32: D95-100.
111. Lee JF, Stovall GM, Ellington AD. Aptamer therapeutics advance. Curr Opin Chem Biol. 2006; 10: 282-9.
112. Bates PJ, Kahlon JB, Thomas SD, Trent JO, Miller DM. Antiproliferative activity of Grich oligonucleotides correlates with protein binding. J Biol Chem. 1999; 274: 26369-77.
113. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the Grich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol. 2009; 86: 151-64.
114. Mongelard F, Bouvet P. AS-1411, a guanosinerich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr Opin Mol Ther. 2010; 12: 107-14.
115. Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol. 2010; 50: 237-57.
116. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 2002; 62: 4029-33.
117. Bagalkot V, Farokhzad OC, Langer R, Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed. 2006; 45: 8149-52.
118. Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA. 2010; 107: 17939-44.
119. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA. 2006; 103: 6315-20.
120. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004; 64: 7668-72.
121. Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 2007; 7: 3065-70.
122. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol. 2009; 27: 839-49.
123. Yu MK, Kim D, Lee IH, So JS, Jeong YY, Jon S. Image-Guided Prostate Cancer Therapy Using Aptamer-Functionalized Thermally Cross-Linked Superparamagnetic Iron Oxide Nanoparticles. Small. 2011; 7: 2241-9.
124. Hwang do W, Ko HY, Lee JH, Kang H, Ryu SH, Song IC, et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med. 2010; 51: 98-105.
125. Derenzini M, Sirri V, Trere D, Ochs RL. The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells. Lab Invest. 1995; 73: 497-502.
126. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals. Eur J Nucl Med Mol Imaging. 2007; 34: 982-93.
127. Li N, Larson T, Nguyen HH, Sokolov KV, Ellington AD. Directed evolution of gold nanoparticle delivery to cells. Chemm Commun. 2010; 46: 392-4.
128. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464: 1067-70.
129. Gatter KC, Brown G, Trowbridge IS, Wollston RE, Mason DY. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol. 1983; 36: 539-45.
130. Cerqueira NM, Pereira S, Fernandes PA, Ramos MJ. Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumor therapy. Curr Med Chem. 2005; 12: 1283-94.
131. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haubmann I, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991; 65:13-24.
132. Platt VM, Szoka Jr FC. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharmaceutics. 2008; 5: 474-86.
133. Bhang SH, Won N, Lee T, Jin H, Nam J, Park J, et al. Hyaluronic acid-quantum dot conjugates for in vivo lymphatic vessel imaging. ACS Nano. 2009; 3: 1389-98.
134. Wu W, Shen J, Banerjee P, Zhou S. Core-shell hybrid nanogels for integration of optical temperature-sensing, targeted tumor cell imaging, and combined chemo-photothermal treatment. Biomaterials. 2010; 31: 7555-66.
135. Ge Y, Zhang Y, He S, Nie F, Teng G, Gu N. Fluorescence Modified Chitosan-Coated Magnetic Nanoparticles for High-Efficient Cellular Imaging. Nanoscale Res Lett. 2009; 4: 287-95.
136. Lee H, Yu MK, Park S, Moon S, Min JJ, Jeong YY, et al. Thermally cross-linked superparamagnetic iron oxide nanoparticles: synthesis and application as a dual imaging probe for cancer in vivo. J Am Chem Soc. 2007; 129: 12739-45.
137. Talanov VS, Regino CA, Kobayashi H, Bernardo M, Choyke PL, Brechbiel MW. Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett. 2006; 6: 1459-63.
138. Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 2010; 62: 284-304.
139. Brunel FM, Lewis JD, Destito G, Steinmetz NF, Manchester M, Stuhlmann H, et al. Hydrazone ligation strategy to assemble multifunctional viral nanoparticles for cell imaging and tumor targeting. Nano Lett. 2010; 10: 1093-7.
140. Destito G, Yeh R, Rae CS, Finn MG, Manchester M. Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. Chem Biol. 2007; 14: 1152-62.
141. Lewis JD, Destito G, Zijlstra A, Gonzalez MJ, Quigley JP, Manchester M, et al. Viral nanoparticles as tools for intravital vascular imaging. Nat Med. 2006; 12: 354-60.
142. McLain L, Durrani Z, Wisniewski LA, Porta C, Lomonossoff GP, Dimmock NJ. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus. Vaccine. 1996; 14: 799-810.
143. Zhang J, Misra RD. Magnetic drug-targeting carrier encapsulated with thermosensitive smart polymer: core-shell nanoparticle carrier and drug release response. Acta Biomater. 2007; 3: 838-50.
144. Xie J, Chen K, Lee HY, Xu C, Hsu AR, Peng S, et al. Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. J Am Chem Soc. 2008; 130: 7542-3.
145. Koole R, van Schooneveld MM, Hilhorst J, Castermans K, Cormode DP, Strijkers GJ, et al. Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging. Bioconjug Chem. 2008; 19: 2471-9.
146. Reddy GR, Bhojani MS, McConville P, Moody J, Moffat BA, Hall DE, et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res. 2006; 12: 6677-86.
147. Yu MK, Park J, Jeong YY, Moon WK, Jon S. Integrin-targeting thermally cross-linked superparamagnetic iron oxide nanoparticles for combined cancer imaging and drug delivery. Nanotechnology. 2010; 21: 415102.
148. Derfus AM, Chen AA, Min DH, Ruoslahti E, Bhatia SN. Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem. 2007; 18: 1391-6.
149. Green NM. Avidin and streptavidin. Methods Enzymol. 1990; 184: 51-67.
150. Mok H, Lee SH, Park JW, Park TG. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat Mater. 2010; 9: 272-8.
151. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V. Iron oxide nanoparticles for sustained delivery of anti-cancer agents. Mol Pharm. 2005; 2: 194-205.
152. Gonzalez H, Hwang SJ, Davis ME. New class of polymers for the delivery of macromolecular therapeutics. Bioconjug Chem. 1999; 10: 1068-74.
153. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-12.
154. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med. 2003; 49: 403-8.
155. Frederick CA, Williams LD, Ughetto G, van der Marel GA, van Boom JH, Rich A, et al. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry. 1990; 29: 2538-49.
156. Kim D, Jeong YY, Jon S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano. 2010; 4: 3689-96.
157. Kolb HC, Finn MG, Sharpless KB. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew Chem Int Ed Engl. 2001; 40: 2004-21.
158. Hein CD, Liu XM, Wang D. Click chemistry, a powerful tool for pharmaceutical sciences. Pharm Res. 2008; 25: 2216-30.
159. Devaraj NK, Upadhyay R, Haun JB, Hilderbrand SA, Weissleder R. Fast and sensitive pretargeted labeling of cancer cells through a tetrazine/trans-cyclooctene cycloaddition. Angew Chem Int Ed Engl. 2009; 48: 7013-6.
160. von Maltzahn G, Ren Y, Park JH, Min DH, Kotamraju VR, Jayakumar J, et al. In vivo tumor cell targeting with "click" nanoparticles. Bioconjug Chem. 2008; 19: 1570-8.
161. Rubinstein DB, Stortchevoi A, Boosalis M, Ashfaq R, Ghebrehiwet B, Peerschke EI, et al. Receptor for the globular heads of C1q (gC1q-R, p33, hyaluronan-binding protein) is preferentially expressed by adenocarcinoma cells. Int J Cancer. 2004; 110: 741-50.
162. Santra S, Kaittanis C, Grimm J, Perez JM. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small. 2009; 5: 1862-8.
163. Haun JB, Devaraj NK, Hilderbrand SA, Lee H, Weissleder R. Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection. Nat Nanotechnol. 2010; 5: 660-5.
164. Haun JB, Devaraj NK, Marinelli BS, Lee H, Weissleder R. Probing intracellular biomarkers and mediators of cell activation using nanosensors and bioorthogonal chemistry. ACS Nano. 2011; 5: 3204-13.
165. Lee H, Yoon TJ, Figueiredo JL, Swirski FK, Weissleder R. Rapid detection and profiling of cancer cells in fine-needle aspirates. Proc Natl Acad Sci U S A. 2009; 106: 12459-64.
166. Javier DJ, Nitin N, Levy M, Ellington A, Richards-Kortum R. Aptamer-targeted gold nanoparticles as molecular-specific contrast agents for reflectance imaging. Bioconjug Chem. 2008; 19: 1309-12.
167. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994; 263: 1600-3.
168. Berry CC, Curtis ASG. Functionalisation of magnetic nanoparticles for applications in biomedicine. Journal of Physics D: Applied Physics. 2003; 36: R198-206.
169. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev. 2001; 53: 283-318.
170. Xie J, Xu C, Kohler N, Hou Y, Sun S. Controlled PEGylation of monodisperse Fe3O4 nanoparticles for reduced nonspecific uptake by macrophage cells. Adv Mater. 2007; 19: 3163-6.
171. Lutz JF, Stiller S, Hoth A, Kaufner L, Pison U, Cartier R. One-pot synthesis of PEGylated ultrasmall iron-oxide nano-particles and their invivo evaluationasmagnetic resonance imaging contrast agents. Biomacromolecules. 2006; 7: 3132-8.
172. Larsen EK, Nielsen T, Wittenborn T, Birkedal H, Vorup-Jensen T, Jakobsen MH, et al. Size-Dependent Accumulation of PEGylated Silane-Coated Magnetic Iron Oxide Nanoparticles in Murine Tumors. ACS Nano. 2009; 3: 1947-51.
173. Chung HJ, Lee H, Bae KH, Lee Y, Park J, Cho SW, et al. Facile synthetic route for surface-functionalized magnetic nanoparticles: cell labeling and magnetic resonance imaging studies. ACS Nano. 2011; 5: 4329-36.
174. Flesch C, Unterfinger Y, Bourgeat-Lami E, Duguet E, Delaite C, Dumas P. Poly(ethylene glycol) surface coated magnetic particles. Macromol Rapid Comm. 2005; 26: 1494-8.
175. Lu Y, Yin YD, Mayers BT, Xia YN. Modifying the surface properties of Superparamagnetic iron oxide nanoparticles through a solgel approach. Nano Lett. 2002; 2: 183-6.
176. Veiseh O, Sun C, Gunn J, Kohler N, Gabikian P, Lee D, et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett. 2005; 5: 1003-8.
177. Gunn J, Wallen H, Veiseh O, Sun C, Fang C, Cao JH, et al. A multimodal targeting nanoparticle for selectively labeling T cells. Small. 2008; 4: 712-5.
178. Sun C, Veiseh O, Gunn J, Fang C, Hansen S, Lee D, et al. In vivo MRI detection of gliomas by chlorotoxin-conjugated super-paramagnetic nanoprobes. Small. 2008; 4: 372-9.
179. Kumar M, Muzzarelli RAA, Muzzarelli C, Sashiwa H, Domb AJ. Chitosan chemistry and pharmaceutical perspectives. Chem Rev. 2004; 104: 6017-84.
180. Park J, Yu MK, Jeong YY, Kim JW, Lee K, Phan VN, et al. Anti-biofouling amphiphilic polymer-coated superparamagnetic iron oxide nanoparticles: synthesis, characterization, and use in cancer imaging in vivo. J Mater Chem. 2009; 19: 6412-7.
181. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, et al. Superparamagnetic iron oxide - pharmacokinetic and toxicity. AJR Am J Roentgenol. 1989; 152: 167-73.
182. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide - an intravenous contrast agent for assessing lymphnodes with MR imaging. Radiology. 1990; 175: 494-8.
183. Stark DD, Weissleder R, Elizondo G, Hahn PF, Saini S, Todd LE, et al. Superparamagnetic iron oxide - clinical application as a contrast agent for MR imaging of the liver. Radiology. 1988; 168: 297-301.
184. Josephson L, Tung CH, Moore A, Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem. 1999; 10: 186-91.
185. Wunderbaldinger P, Josephson L, Weissleder R. Cross-linked iron oxides (CLIO): A new platform for the development of targeted MR contrast agents. Acad Radiol. 2002; 9: S304-6.
186. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev. 2008; 60: 1241-51.
187. Wang Y, Teng XW, Wang JS, Yang H. Solvent-free atom transfer radical polymerization in the synthesis of Fe2O3 at polystyrene core-shell nanoparticles. Nano Lett. 2003; 3: 789-93.
188. Li GF, Fan JD, Jiang R, Gao Y. Cross-linking the linear polymeric chains in the ATRP synthesis of iron oxide/polystyrene core/shell nanoparticles. Chem Mater. 2004; 16: 1835-7.
189. Chastellain M, Petri A, Hofmann H. Superparamagnetic iron oxide nanoparticles for biomedical applications: a focus on PVA as a coating. Quantum Dots, Nanoparticles and Nanowires 2004; 789: 269-72.
190. Liu HL, Ko SP, Wu JH, Jung MH, Min JH, Lee JH, et al. One-pot polyol synthesis of monosize PVP-coated sub-5 nm Fe3O4 nanoparticles for biomedical applications. J Magn Magn Mater. 2007; 310: E815-7.
191. Ma YH, Wu SY, Wu T, Chang YJ, Hua MY, Chen JP. Magnetically targeted thrombolysis with recombinant tissue plasminogen activator bound to polyacrylic acid-coated nanoparticles. Biomaterials. 2009; 30: 3343-51.
192. Portet D, Denizot B, Rump E, Lejeune JJ, Jallet P. Nonpolymeric coatings of iron oxide colloids for biological use as magnetic resonance imaging contrast agents. J Colloid Interface Sci. 2001; 238: 37-42.
193. Fauconnier N, Pons JN, Roger J, Bee A. Thiolation of maghemite nanoparticles by dimercaptosuccinic acid. J Colloid Interface Sci. 1997; 194: 427-33.
194. Zhang C, Wangler B, Morgenstern B, Zentgraf H, Eisenhut M, Untenecker H, et al. Silica- and alkoxysilanecoated ultrasmall superparamagnetic iron oxide particles: a promising tool to label cells for magnetic resonance imaging. Langmuir. 2007; 23: 1427-34.
195. Jun YW, Huh YM, Choi JS, Lee JH, Song HT, Kim S, et al. Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J Am Chem Soc. 2005; 127: 5732-3.
196. Choi JS, Park JC, Nah H, Woo S, Oh J, Kim KM, et al. A hybrid nanoparticle probe for dual-modality positron emission tomography and magnetic resonance imaging. Angew Chem Int Ed Engl. 2008; 47: 6259-62.
197. Lee JH, Lee K, Moon SH, Lee Y, Park TG, Cheon J. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew Chem Int Ed Engl. 2009; 48: 4174-9.
198. Martina MS, Fortin JP, Ménager C, Clément O, Barratt G, Grabielle-Madelmont C, et al. Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. J Am Chem Soc. 2005; 127: 10676-85.
199. Yang J, Lee CH, Ko HJ, Suh JS, Yoon HG, Lee K, et al. Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angew Chem Int Ed Engl. 2007; 46: 8836-9.
200. Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, Guthi JS, et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett. 2006; 6: 2427-30.
201. Kim J, Kim HS, Lee N, Kim T, Kim H, Yu T, et al. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew Chem Int Ed Engl. 2008; 47: 8438-41.
202. Kim J, Park S, Lee JE, Jin SM, Lee JH, Lee IS, et al. Designed fabrication of multifunctional magnetic gold nanoshells and their application to magnetic resonance imaging and photo-thermal therapy. Angew Chem Int Ed Engl. 2006; 45: 7754-8.
203. Zhang Z, Chao T, Chen SF, Jiang SY. Superlow fouling sul-fobetaine and carboxybetaine polymers on glass slides. Langmuir 2006; 22: 10072-7.
204. Ostuni E, Chapman RG, Liang MN, Meluleni G, Pier G, Ingber DE, et al. Self-assembled monolayers that resist the adsorption of proteins and the adhesion of bacterial and mammalian cells. Langmuir. 2001; 17: 6336-43.
205. Ladd J, Zhang Z, Chen S, Hower JC, Jiang S. Zwitterionic polymers exhibiting high resistance to nonspecific protein adsorption from human serum and plasma. Biomacromolecules. 2008; 9: 1357-61.
206. Holmlin RE, Chen XX, Chapman RG, Takayama S, Whitesides GM. Zwitterionic SAMs that resist nonspecific adsorption of protein from aqueous buffer. Langmuir. 2001; 17: 2841-50.
207. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007; 25: 1165-70.
208. Liu W, Choi HS, Zimmer JP, Tanaka E, Frangioni JV, Bawendi M. Compact cysteine-coated CdSe(ZnCdS) quantum dots for in vivo applications. J Am Chem Soc. 2007; 129: 14530-1.
209. Yang W, Zhang L, Wang S, White AD, Jiang S. Functionalizable and ultra stable nanoparticles coated with zwitterionic poly(carboxybetaine) in undiluted blood serum. Biomaterials. 2009; 30: 5617-21.
210. Zhang L, Xue H, Gao C, Carr L, Wang J, Chu B, et al. Imaging and cell targeting characteristics of magnetic nanoparticles modified by a functionalizable zwitterionic polymer with ad-hesive 3,4-dihydroxyphenyl-l-alanine linkages. Biomaterials. 2010; 31: 6582-8.
211. Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008; 60: 1252-65.
212. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl. 2010; 49: 6288-308.
213. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res. 2010; 62: 90-9.
214. Degennes PG. Polymers at an interface-a simplified view. Adv Colloid Interface. 1987; 27: 189-209.
215. Szleifer I. Polymers proteins: interactions at interfaces. Curr Opin Solid St M. 1997; 2: 337-44.
216. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006; 307: 93-102.
217. Gbadamosi JK, Hunter AC, Moghimi SM. PEGylation of mi-crospheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. Febs Lett. 2002; 532: 338-44.
218. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev. 1995; 17: 31-48.
219. Garg A, Tisdale AW, Haidari E, Kokkoli E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int J Pharm. 2009; 366: 201-10.
220. Gindy ME, Ji S, Hoye TR, Panagiotopoulos AZ, Prud'homme RK. Preparation of poly(ethylene glycol) protected nanoparticles with variable bioconjugate ligand density. Biomacromolecules. 2008; 9: 2705-11.
221. Olivier V, Meisen I, Meckelein B, Hirst TR, Peter-Katalinic J, Schmidt MA, et al. Influence of targeting ligand flexibility on receptor binding of particulate drug delivery systems. Bioconjug Chem. 2003; 14: 1203-8.
222. Ferrari M. Nanogeometry: beyond drug delivery. Nat Nanotechnol. 2008; 3: 131-2.
223. Fakhari A, Baoum A, Siahaan TJ, Le KB, Berkland C. Controlling ligand surface density optimizes nanoparticle binding to ICAM-1. J Pharm Sci. 2011; 100: 1045-56.
224. Wülfing C, Sjaastad MD, Davis MM. Visualizing the dynamics of T cell activation: intracellular adhesion molecule 1 migrates rapidly to the T cell/B cell interface and acts to sustain calcium levels. Proc Natl Acad Sci U S A. 1998; 95: 6302-7.
225. Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A. 2008; 105: 2586-91.
226. Shmeeda H, Tzemach D, Mak L, Gabizon A. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. J Control Release. 2009; 136: 155-60.
227. Park JH, von Maltzahn G, Zhang L, Derfus AM, Simberg D, Harris TJ, et al. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small. 2009; 5: 694-700.